Characterizing AAV Capsids with Label-Free Biosensor Technology

1. What specific limitations in fluorescence-based and traditional immunoassays, particularly in the context of AAV capsid characterization, were addressed by adopting label-free biosensor technologies in your study?

The adoption of BLI has brought two major improvements to our analyses compared to traditional techniques like ELISA or fluorescence labeling.

First, it offers a significant time-saving advantage for an equivalent consumable cost when processing the same number of samples, allowing for the analysis of a greater number of samples.

Second, it has led to a significant reduction in the variability observed between experiments, as BLI demonstrates strong reproducibility over time compared to the results we obtained with ELISA.

Furthermore, the absence of any labeling treatment and the ability to monitor interactions in real-time enable much more efficient analysis monitoring, offering greater flexibility and adaptability in our workflows. This approach also avoids potentially altering the capsids being analyzed, ensuring the method is non-destructive to the sample and allowing its reuse for other analytical approaches.

2. Biolayer interferometry (BLI) is widely used in protein interaction studies. What specific adaptations or calibrations were necessary to optimize this technology for high-throughput AAV capsid characterization?

In reality, very little.

As an anecdote, when we first started quantifying AAV capsids in our samples, the AAVX biosensors that allow this on BLI did not yet exist. We therefore developed them internally, based on the CaptureSelectTM AAVX, which is precisely the foundation of the AAVX biosensors. This development occurred in parallel with the one at Sartorius and was no more complex than a standard development for protein quantification using BLI.

We needed to optimize the loading on the biosensors and establish the quantification limits for each AAV considered. Similarly, we verified the potential effects of the buffers used as well as the feasibility of regenerating the biosensors to reduce costs by enabling their reuse across multiple samples. Beyond this, there was no significant impact on our AAV production methods.

Now, the availability of pre-prepared AAVX biosensors further reduces potential variations associated with biosensor loading, streamlining the process even more.

3. Given that AAV capsids are known for their complex structure and potential heterogeneity, how does BLI account for or mitigate potential interference from capsid heterogeneity in both purified and crude samples?

This technique's sensitivity is both its strength and potentially its weakness.

It is therefore crucial to thoroughly characterize the samples and, above all, to monitor them constantly. The observed behavior may not necessarily be the same for a purified sample compared to a crude one.

The matrix can have a significant impact, and steps such as filtration or buffer adjustment can greatly help reduce interferences caused by contaminants or partial or aggregated capsids. Ideally, a standard prepared in a matrix identical to that of the samples is preferable.

However, one of the key advantages of BLI is that data acquisition does not prevent revisiting and reanalyzing the data retrospectively. Parameters can be adjusted based on additional insights that may emerge later, offering flexibility and adaptability in the analysis process.

4. In your experience, how does the precision of label-free biosensors compare with high-resolution structural techniques like cryo-EM when characterizing viral capsids? Are there complementary benefits of combining these methods?

I wouldn’t say they are comparable but rather complementary. High-resolution techniques provide unparalleled precision due to their atomic-level approach to capsid structures, but this comes at a much higher per-sample cost and is also limited in throughput.

In contrast, BLI excels in large-scale quantification and kinetic analysis. For me, these two methods are entirely complementary, depending on the information required.

For production screening and candidate selection, BLI offers rapid access to critical information, such as identifying the best producers or candidates. Meanwhile, techniques like cryo-EM are better suited for finely characterizing a selected product destined for a specific application.

5. What key factors influence the binding kinetics observed in BLI when assessing AAV capsid concentrations? How do these compare with traditional kinetic models used in other viral studies?

As mentioned earlier, the buffer composition is a key factor, as is the composition of the sample and the integrity of the capsids being produced and measured.

Similarly, changes in buffer composition, such as salinity, pH, or the presence of other molecules that may act as chaperones or interact with the capsids, can influence the interaction kinetics between the capsid and the biosensor. It is therefore essential to use an identical matrix for all samples and the standard to minimize potential effects that could distort the results. Additionally, it is important to define in advance, through testing, whether certain parameters of this matrix might cause issues.

6. Can you discuss the technical parameters optimized for this study, such as probe selection, buffer composition, assay sensitivity thresholds, or temperature? How critical were these adjustments to the study’s success?

For me, there are five essential parameters that must always be kept in mind when conducting an analysis to ensure reproducibility and reliability of the measurements.

As previously mentioned, the choice of probe specificity is crucial, as a highly specific biosensor will inherently reduce non-specific interactions. AAVX is an excellent choice for quantifying AAV capsids, but it is also possible to use other specific molecules through tailored development. Buffers are also a critical factor, as they not only minimize non-specific interactions or improve specific binding but also help stabilize the capsids. The sensitivity threshold is another key point, as it defines the conditions for detecting intact or partial capsids as well as full or empty ones. Temperature is important as it can influence the kinetics of the interaction. Finally, the regenerability of the biosensors is crucial. It is essential to determine whether the biosensors can be regenerated in a given matrix without losing part of their binding capacity.

7. What insights did label-free biosensor technology (or BLI) provide regarding the stability of AAV capsids under varying production or storage conditions, particularly in relation to long-term stability for gene therapy applications?

The reproducibility of measurements using a defined standard allows for monitoring not only in real-time but also over longer periods, such as during stability studies or investigations into the impact of freeze-thaw cycles on capsids or the effect of temperature on capsid integrity.

This enables a better definition of the shelf life of formulations potentially used for storing or administering AAVs in the context of human health.

8. Label-free biosensors are praised for their real-time analysis capabilities. Could you discuss the challenges and benefits of this feature in monitoring batch-to-batch consistency in AAV production, especially for clinical-scale applications?

The advantages are quite clear:

- Immediate monitoring of discrepancies between different batches.
- Rapid identification of potential production defects.
- Cost reduction by quickly identifying and limiting defective samples.

However, this also implies associated disadvantages, such as the need to maintain calibrated equipment for large-scale productions and a perfectly defined standard in terms of both composition and long-term stability.

9. How does label-free biosensor technology (or BLI) integrate with or enhance other quality control techniques currently employed in regulatory workflows for gene therapy production (e.g., purity assessments, particle counting)?

BLI plays a complementary role to the techniques currently used to evaluate AAV vector production.

Unlike SDS-PAGE or HPLC, which assess chemical purity, BLI provides additional information on the possible presence of contaminants or non-compliant capsids through the analysis of specific interactions between capsids and the chosen ligands. This is achieved without requiring additional labeling steps, which can make the process lengthy and costly.

Furthermore, BLI is versatile enough to allow quantification while differentiating between intact, empty, or partially formed capsids—all in real-time and at high throughput.

For us, it is an excellent complement to the accepted "gold standards" for viral vector quality control, integrating seamlessly into a regulatory ecosystem and even reinforcing expectations regarding imposed standards.

10. To what extent can label-free biosensors differentiate between intact and partial AAV capsids? What are the implications of this capability for ensuring therapeutic efficacy and safety in gene therapy?

As previously mentioned, it is entirely possible to differentiate between intact, filled capsids and those that are partial or empty.

This differentiation is achieved through the binding kinetics of each particle, whether intact or partial. Differences in kinetics can be observed and monitored, particularly through weaker affinity when a particle is damaged, which is often associated with the degradation of critical binding epitopes necessary for the interaction.

Thus, distinguishing between intact and partial particles ensures a homogeneous population of functional capsids. This not only guarantees the safety of the product but also minimizes potential immune responses while maximizing its efficiency in delivering genetic material.

11. Given the increasing demand for scalable gene therapy solutions, how does this technology support the needs of biopharma manufacturing at an industrial scale, particularly in terms of throughput and consistency?

It's very simple.

Through a high-throughput analysis approach with increased consistency and repeatability, BLI seamlessly integrates into production pipelines at every stage. This automation also significantly reduces human error and ensures compliance with product standards, batch after batch.

Additionally, it lowers the cost of analysis, whether through its high-throughput and automated approach or at each step of production. This enables the rapid identification of batches that fail to meet requirements, avoiding costly production processes associated with non-compliant batches.

12. Can you elaborate on the validation process for this label-free approach to ensure it meets regulatory standards, particularly in light of evolving guidelines for gene therapy products?

Regulatory standards represent a well-defined framework with numerous analytical processes that must be established, validated, and adhered to. The advantage of BLI technology lies in its versatility while offering robustness across many aspects. It allows for the validation of diverse samples under various conditions, enabling controlled variation of parameters.

Moreover, the technique’s strong robustness provides the reproducibility necessary for product validation, combined with demonstrated precision when compared to other established techniques. The entire process can be thoroughly documented, which is essential for acceptance by regulatory agencies. Additionally, its adaptability ensures it remains a sustainable choice as standards continue to evolve.

Once again, the method's robustness and versatility are its key strengths for adoption in monitoring and validating AAV production processes.

13. In your opinion, how will the widespread adoption of label-free biosensor technologies impact the future of AAV capsid characterization and the development of next-generation gene therapy vectors?

From our perspective, this seems quite clear.

This technology enables simpler, faster monitoring at every stage of production to validate the AAVs being produced. It allows for quicker optimization of formulations and production processes for gene therapies while ensuring greater uniformity and quality of capsids—key factors for achieving successful treatments.

Additionally, thanks to its flexibility, the robustness of its results, and its high-throughput approach, it reduces costs, making gene therapies more affordable. It also facilitates the development of vectors tailored to specific and more personalized needs, while still ensuring compliance with regulatory standards.

In conclusion, BLI is a technological advancement that supports the growth of gene therapy development by ensuring quality, efficiency, and scalability.

--Issue 05--